U.S. DOJ Reclassifies Marijuana Products to Schedule III

This shift in federal policy signals a potential easing of restrictions that could enhance medical research and market opportunities in the cannabis sector.

• On April 23, 2026, the U.S. Department of Justice reclassified FDA-approved and state-licensed medical marijuana products from Schedule I to Schedule III.
• Acting Attorney General Todd Blanche announced the immediate implementation, fulfilling President Trump's December 2025 executive order aimed at expanding medical research.
• An expedited hearing for broader marijuana rescheduling is set for June 29, 2026, while recreational marijuana remains federally illegal.

• Marijuana has been classified as Schedule I since 1970, indicating high abuse potential and no accepted medical use, despite state-level legalization efforts.
• President Biden's administration proposed rescheduling in 2024, but the Trump administration halted those efforts upon taking office.
• The reclassification allows for tax relief under Section 280E for affected businesses, potentially easing financial burdens and improving banking access.

The reclassification of marijuana products by the U.S. Department of Justice (DOJ) marks a significant shift in federal drug policy, driven by a combination of political will and evolving public perception. Historically, marijuana has been classified as a Schedule I substance under the Controlled Substances Act, which denotes a high potential for abuse and no accepted medical use. This classification has long hindered research and development in the cannabis sector, despite growing evidence of its medical benefits and the legalization efforts at the state level.

The impetus for this change can be traced back to President Trump's executive order issued on December 18, 2025, which aimed to accelerate medical marijuana research and align federal policy with state regulations. This order recognized the need to adapt to the realities of state-level legalization and international treaty obligations. The DOJ's decision to reclassify FDA-approved and state-licensed medical marijuana products to Schedule III is a direct response to this executive directive, allowing for a more nuanced approach to cannabis regulation.

The immediate implications of this reclassification are significant. It eases federal restrictions on specific marijuana products, enabling greater access for patients and facilitating research into their medical applications. However, it does not legalize recreational marijuana at the federal level, maintaining a clear distinction between medical and recreational use. This nuanced approach reflects a growing recognition of the therapeutic potential of cannabis while still addressing concerns about abuse and public health.

Moreover, the reclassification opens the door for cannabis companies to benefit from tax relief under Section 280E, which has historically imposed heavy tax burdens on businesses operating in the cannabis space. This could lead to increased profitability and investment in the sector, as companies gain better access to banking services and financial resources. However, the initial market reaction was mixed, with cannabis stocks experiencing a surge of 6-13% before retreating as investors assessed the limited immediate scope of the reclassification.

As the expedited hearing for broader rescheduling approaches on June 29, 2026, the cannabis industry is poised for further developments. The outcome of this hearing could determine the future trajectory of cannabis regulation in the U.S., potentially paving the way for more comprehensive reforms.

• Cannabis companies: They may see increased investment opportunities and reduced tax burdens.
• Patients: Access to FDA-approved medical marijuana products could improve, enhancing treatment options.
• Investors: Those in the cannabis sector may experience volatility as the market adjusts to the new regulations.
• Healthcare providers: They may gain more resources for research and treatment options involving medical marijuana.

• June 29, 2026, hearing outcomes: This will determine the future of broader marijuana rescheduling and could signal further regulatory changes.
• Market reactions: Watch for stock performance of cannabis companies as they adapt to the new regulations and potential tax relief.
• State-level responses: Monitor how individual states adjust their cannabis policies in light of federal changes, particularly regarding recreational use.